PRL and DNA damage alter the immune response to breast cancer cells

作者: Karayazi Atici , Shemanko

DOI: 10.1101/2020.08.31.274357

关键词:

摘要: There are conflicting reports of the role prolactin in breast cancer, and its within context tumour microenvironment is not well understood. In our previous study, we demonstrated a cross-talk between ataxia telangiectasia-mutated (ATM) DNA damage response pathway PRL-Janus-kinase-2 (JAK2)-signal transducer activator transcription-5 (STAT5)-heat shock protein-90 (HSP90) pathway. order to investigate PRL initiation effect vivo, used model cancer that assesses ability cells initiate orthotopic xenograft formation after damage. Breast engineered secrete human or control cells, were treated with damaging agent doxorubicin vehicle injected into mammary fat pad immune deficient SCID mice. secretion from did change latency compared controls, although combined treatment increased latency. Injection natural killer (NK) cell-depleting antibody, anti-asialo GM1, resulted faster only PRL-secreting pre-treated doxorubicin, PRL-only empty vector controls. These results may shed light on demonstrate at least cell damage, exposure does delay initiation, but together reduced volume over time due asialo-GM1-positive cells.

参考文章(46)
Kathleen A. O’Leary, Michael P. Shea, Linda A. Schuler, Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Advances in Experimental Medicine and Biology. ,vol. 846, pp. 201- 220 ,(2015) , 10.1007/978-3-319-12114-7_9
Erik Wennerberg, Dhifaf Sarhan, Mattias Carlsten, Vitaliy O. Kaminskyy, Padraig D'Arcy, Boris Zhivotovsky, Richard Childs, Andreas Lundqvist, Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. International Journal of Cancer. ,vol. 133, pp. 1643- 1652 ,(2013) , 10.1002/IJC.28163
Alessandra Soriani, Maria Luisa Iannitto, Biancamaria Ricci, Cinzia Fionda, Giulia Malgarini, Stefania Morrone, Giovanna Peruzzi, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Marco Cippitelli, Angela Santoni, Reactive Oxygen Species– and DNA Damage Response–Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1 The Journal of Immunology. ,vol. 193, pp. 950- 960 ,(2014) , 10.4049/JIMMUNOL.1400271
Tomohiro Yonezawa, Kuan-Hui (Ethan) Chen, Mrinal K. Ghosh, Lorena Rivera, Riva Dill, Lisa Ma, Pedro A. Villa, Mitsumori Kawaminami, Ameae M. Walker, Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer Cancer Letters. ,vol. 366, pp. 84- 92 ,(2015) , 10.1016/J.CANLET.2015.06.010
Sommer L. Miller, Jamie E. DeMaria, David O. Freier, Angela M. Riegel, Charles V. Clevenger, Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Molecular Endocrinology. ,vol. 19, pp. 939- 949 ,(2005) , 10.1210/ME.2004-0443
H Wennbo, M Gebre-Medhin, A Gritli-Linde, C Ohlsson, O G Isaksson, J Törnell, Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice Journal of Clinical Investigation. ,vol. 100, pp. 2744- 2751 ,(1997) , 10.1172/JCI119820
Rui SUN, Ai Ling LI, Hai Ming WEI, Zhi Gang TIAN, Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines Cell Research. ,vol. 14, pp. 67- 73 ,(2004) , 10.1038/SJ.CR.7290204
NIRA BEN-JONATHAN, JOHN L. MERSHON, DONALD L. ALLEN, ROSEMARY W. STEINMETZ, Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects* Endocrine Reviews. ,vol. 17, pp. 639- 669 ,(1996) , 10.1210/EDRV-17-6-639
C J Chan, M J Smyth, L Martinet, Molecular mechanisms of natural killer cell activation in response to cellular stress Cell Death & Differentiation. ,vol. 21, pp. 5- 14 ,(2014) , 10.1038/CDD.2013.26